RecruitingNot ApplicableNCT07461090

Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis

Sponsor

Menoufia University

Enrollment

60 participants

Start Date

Feb 1, 2026

Study Type

INTERVENTIONAL

Conditions

Renal Cell Carcinoma (RCC)Nonfunctioning Kidney

Summary

To evaluate and compare clinical effectiveness (operative time, blood loss, hospital stay, complications and etc) and cost analysis' between laparoscopic nephrectomy and open nephrectomy .

Eligibility

Min Age: 1 Year

Inclusion Criteria7

American Society of Anesthesiology score 1-3.
Indication for :
Simple total nephrectomy or hemi nephrectomy: benign chronic inflammatory non-functioning kidney
Partial nephrectomy: localized renal mass ≤7 cm suitable for nephron-sparing surgery.
Radical nephrectomy or Radical nephrouretrectomy with bladder cuff: localized renal tumor requiring complete nephrectomy without major vascular invasion.
Patient deemed fit for general anesthesia and surgery.
Patient provides written informed consent.

Exclusion Criteria9

emergency surgery, dialysis-dependent patients, planned hybrid procedures.
Patients with incomplete data
Patients with metastatic disease at presentation.
Prior extensive ipsilateral retroperitoneal surgery or severe adhesions precluding Laparoscopy.
Need for concomitant major procedures (eg, large bowel resection) at index operation.
Locally advanced tumor with obvious major vascular involvement requiring complex vascular reconstruction.
Uncorrected coagulopathy.
Pregnancy or Obese patient (BMI \> 40)
Inability to provide informed consent or comply with follow-up.

Interventions

PROCEDUREopen or laparoscopic nephrectomy

compare post operative recovery , estimated blood loss and cost analysis between open and laparosopic nephrectomy.

Locations(1)

Menoufia Faculty of Medicine

Shibīn al Kawm, Shebin Elkom, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07461090

Related Trials

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

NCT05176483122 locations

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

NCT06661720399 locations